The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsAgustsson, Tomas Thor
Jonasson, Jon G
Thorsson, Arni V
Carroll, Paul V
MetadataShow full item record
CitationThe epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. 2015, 173 (5):655-64 Eur. J. Endocrinol.
AbstractPituitary adenomas (PA) are among the most common human neoplasms. To describe the epidemiology and assess the disease burden of clinically significant PAs, population-based studies are needed. Iceland has a small well-defined population. The aim of this study is to describe the epidemiology of PAs in Iceland over an expanded period of time.
This is a retrospective observational study, including all PAs diagnosed in Iceland from 1955 to 2012.
Extensive clinical information was gathered in a database. Prevalence rates for all PA subtypes were calculated along with standardized incidence rates (SIR). Sex ratios and relationships with adenoma size, age, and symptoms were assessed.
We identified 471 individuals: 190 men and 281 women. Total prevalence in 2012 was 115.57/100, 000, prolactinomas were most prevalent (54.37/100, 000) followed by non-functioning adenomas (NFPAs) (42.32/100 ,000). Throughout the period, NFPAs were most common (43.0%) followed by prolactinomas (39.9%) and 11.3% had acromegaly and 5.7% Cushing's disease. Women are diagnosed younger with smaller adenomas. Total SIR has increased significantly and is now 5.8/100 000 per year.
In this nationwide study spanning six decades, we have confirmed PAs rising prevalence and incidence rates noted in recent studies. We demonstrated higher overall prevalence and incidence rates than ever previously recorded with an increasing predominance of NFPAs, which is not explained by incidental findings alone. There is a relationship with the introduction of imaging modalities, but the vast majority of patients are symptomatic at diagnosis. This underlines the importance of increased awareness, education, and appropriate allocation of resources for this growing group of patients.
DescriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the page
RightsArchived with thanks to European journal of endocrinology / European Federation of Endocrine Societies
- The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011.
- Authors: Tjörnstrand A, Gunnarsson K, Evert M, Holmberg E, Ragnarsson O, Rosén T, Filipsson Nyström H
- Issue date: 2014 Oct
- Incidence of pituitary adenomas in Northern Finland in 1992-2007.
- Authors: Raappana A, Koivukangas J, Ebeling T, Pirilä T
- Issue date: 2010 Sep
- High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium.
- Authors: Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A
- Issue date: 2006 Dec
- Incidence and prevalence of clinically relevant pituitary adenomas: retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina.
- Authors: Day PF, Loto MG, Glerean M, Picasso MF, Lovazzano S, Giunta DH
- Issue date: 2016 Nov-Dec
- Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).
- Authors: Fernandez A, Karavitaki N, Wass JA
- Issue date: 2010 Mar